Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
|Articles|October 28, 2011
Quiz on Bipolar Disorder
Author(s)Psychiatric Times Editors
On the BSDS what score range indicates that there is a moderate probability of bipolar spectrum disorder? During euthymia, bipolar patients may have chronic impulsivity that predisposes them to aggression-especially those with comorbid features of which disorder? These questions and more in this quiz.
Advertisement
On the BSDS what score range indicates that there is a moderate probability of bipolar spectrum disorder? During euthymia, bipolar patients may have chronic impulsivity that predisposes them to aggression-especially those with comorbid features of which disorder? These questions and more in this quiz.
Advertisement
Related to this article
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psychiatric Pipeline in Review: Quarter 3, 2026
2
Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression
3
VA Expands Informed Consent Requirements for Psychotropic Medications Starting in 2027
4
September 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
5